Streetbeat News

Stock Prices

HDB

HDFC Bank Ltd (NYSE: HDB) reported a Q2 consolidated net revenue increase of 114.8% Y/Y to INR 66,317 crore ($8.02 billion). The company's consolidated profit after tax rose 51.1%. On a standalone basis, the Bank's net revenue rose by 33.1% Y/Y. Net interest income grew 30.3% Y/Y. Total deposits stood at INR 21,72,858 crore (+29.8% Y/Y), and gross advances came in at INR 23,54,633 crore (+57.7% Y/Y). Gross non-performing assets stood at 1.34% of gross advances. HDB shares are trading higher by 1.94% at $59.33.

Portfolio Pulse from Lekha Gupta

October 16, 2023 | 4:08 pm

ALDX

CNSL

ETWO

OMER

PCTI

SCHW

STRM

U.S. stocks traded higher with the Nasdaq Composite gaining more than 100 points. Charles Schwab Corporation reported better-than-expected earnings for Q3, despite a 16% YoY decline in net revenue. Consolidated Communications Holdings, PCTEL, and E2open Parent Holdings saw their shares rise following acquisition announcements and stake reporting. Aldeyra Therapeutics, Streamline Health Solutions, and Omeros Corporation saw their shares drop due to FDA feedback, strategic restructuring, and discontinuation of a trial respectively.

Portfolio Pulse from Lisa Levin

October 16, 2023 | 4:08 pm

SWAV

ShockWave Medical (NASDAQ:SWAV) has received various analyst ratings in the last quarter, with 1 bullish, 2 somewhat bullish, and 2 indifferent. The average price target is $275.0, compared to the current price of $200.71, implying an upside. However, this average represents a 11.77% decrease from the previous average price target of $311.67.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

BIIB

An industry comparison of Biogen (NASDAQ:BIIB) and its primary competitors in the Biotechnology industry reveals that Biogen's low PE, PB, and PS ratios suggest that the company's stock is undervalued. However, Biogen's low ROE, EBITDA, gross profit, and high revenue growth may indicate challenges in generating profits and managing expenses.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

EXLS

ExlService Holdings (NASDAQ:EXLS) has received various analyst ratings in the last quarter, with 1 bullish, 4 somewhat bullish, and 3 indifferent. The average price target is $107.62, a significant increase from the current price of $29.47. However, this average has decreased by 21.96% from the previous average price target of $137.90.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

ARMK

Over the past 3 months, 14 analysts have published their opinion on Aramark (NYSE:ARMK) stock. The average price target is $38.46, implying an upside from the current price of $25.35. This represents a 11.57% decrease from the previous average price target of $43.49.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

AZN

A comprehensive industry comparison of AstraZeneca (NASDAQ:AZN) and its primary competitors in the Pharmaceuticals industry reveals that AstraZeneca's P/E ratio is higher than the industry average, suggesting a premium valuation. However, its P/B and P/S ratios are below the industry average, indicating potential undervaluation. The company's ROE, EBITDA, and gross profit are lower than the industry average, suggesting potential inefficiencies and financial challenges. However, AstraZeneca's revenue growth outperforms the industry average.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

SNOW

Snowflake's (NYSE:SNOW) short percent of float has fallen 15.61% since its last report, with 9.29 million shares sold short, which is 2.92% of all regular shares available for trading. This decrease in short interest could indicate a more bullish market sentiment towards Snowflake. Compared to its peers, Snowflake has less short interest as a percentage of float, with an average of 5.55%.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

PKX

POSCO Holdings's (NYSE:PKX) short percent of float has fallen 4.35% since its last report, indicating a decrease in bearish sentiment towards the stock. The company has 1.34 million shares sold short, which is 0.44% of all regular shares available for trading. Compared to its peers, POSCO has less short interest.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

AVGO

Broadcom (NASDAQ:AVGO) is compared with its competitors in the Semiconductors & Semiconductor Equipment industry. The company's P/E ratio of 27.17 is below the industry average, suggesting undervaluation. However, its P/B ratio of 16.51 and P/S ratio of 10.41 are above the industry average, indicating potential overvaluation. Broadcom's ROE of 14.98% is higher than the industry average, suggesting efficient use of equity. However, its EBITDA, gross profit, and revenue growth are lower than the industry average, indicating potential financial challenges.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm